FY2025 EPS Estimates for ICON Public Cut by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR - Free Report) - Analysts at Leerink Partnrs cut their FY2025 EPS estimates for ICON Public in a research report issued on Monday, January 6th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings of $13.98 per share for the year, down from their prior estimate of $14.11. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for ICON Public's current full-year earnings is $13.42 per share. Leerink Partnrs also issued estimates for ICON Public's FY2026 earnings at $15.81 EPS and FY2027 earnings at $17.82 EPS.

ICLR has been the topic of a number of other research reports. Baird R W cut ICON Public from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 24th. Truist Financial reaffirmed a "buy" rating and set a $284.00 price target (down from $295.00) on shares of ICON Public in a research report on Wednesday, December 18th. The Goldman Sachs Group decreased their price objective on shares of ICON Public from $370.00 to $280.00 and set a "buy" rating for the company in a research report on Friday, October 25th. Barclays lowered their price objective on shares of ICON Public from $330.00 to $275.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. Finally, StockNews.com downgraded shares of ICON Public from a "buy" rating to a "hold" rating in a research note on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $287.00.

ICON Public Stock Down 1.5 %

ICLR traded down $3.24 during trading hours on Wednesday, hitting $219.34. 1,021,825 shares of the company's stock were exchanged, compared to its average volume of 698,619. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 1-year low of $183.38 and a 1-year high of $347.72. The stock's 50-day moving average is $211.60 and its two-hundred day moving average is $273.51. The stock has a market cap of $18.09 billion, a price-to-earnings ratio of 24.45, a PEG ratio of 1.54 and a beta of 1.20.

ICON Public (NASDAQ:ICLR - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period in the prior year, the business posted $3.10 EPS. The firm's quarterly revenue was down 1.2% compared to the same quarter last year.

Institutional Trading of ICON Public

A number of institutional investors have recently bought and sold shares of the business. Arkadios Wealth Advisors raised its position in shares of ICON Public by 5.0% in the third quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company's stock valued at $371,000 after buying an additional 62 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company's stock valued at $147,000 after acquiring an additional 96 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of ICON Public by 39.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company's stock valued at $129,000 after acquiring an additional 111 shares during the period. First Horizon Advisors Inc. grew its holdings in shares of ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company's stock worth $172,000 after purchasing an additional 151 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock worth $91,000 after purchasing an additional 169 shares during the period. Institutional investors own 95.61% of the company's stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.